Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 336 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... December 18, 2020 EMA Recommends Extension of Indications for Idecabtagene Vicleucel February 6, 2024 Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma April 17, 2018 Load more HOT NEWS EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... Can Age Affect Response to Immune Checkpoint Inhibitors? ESMO Launches Living Guidelines to Enhance the Usability of its Clinical...
